1. Articles in category: News

    1-24 of 188 1 2 3 4 5 6 7 8 »
    1. Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      J Pediatr Surg. 2017 Aug 26;:

      Authors: Kawakubo N, Tanaka S, Kinoshita Y, Tajiri T, Yonemitsu Y, Taguchi T

      Abstract PURPOSE: In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma.

      Read Full Article
    2. GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      Cancer Discov. 2017 Sep 22;:

      Authors:

      Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

      PMID: 28939655 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Antibody
    3. When good immune cells turn bad

      When good immune cells turn bad

      Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have identified new findings about an immune cell - called a tumor-associated macrophage - that promotes cancer instead of fighting it. They have identified the molecular pathway, known as STAT3, as the mechanism the immune cell uses to foster neuroblastoma, a pediatric cancer, and have demonstrated use of a clinically available agent, ruxolitinib, to block the pathway.

      Read Full Article
    4. Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Bioorg Med Chem Lett. 2017 Sep 09;:

      Authors: Takahashi N, Koyama S, Hasegawa S, Yamasaki M, Imai M

      Abstract Neuroblastoma is an aggressive and drug-resistant refractory cancer.

      Read Full Article
      Mentions: Refractory
    5. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    6. Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies

      Background: The purpose of this study was to determine the feasibility and tolerability of tandem courses of high-dose thiotepa with autologous hematopoietic cell rescue (AHCR) in patients with recurrent, refractory solid tumors who were ineligible for a single course of high-dose therapy due to greater than minimal residual disease. Patients with decreased hearing or poor renal function were eligible.

      Read Full Article
      Mentions: Refractory
    7. Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Cancer Cell. 2017 Sep 11;32(3):271-273

      Authors: Malone CF, Stegmaier K

      Abstract In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

      Read Full Article
      Mentions: Antibody
    8. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy--harnessing the immune system in medical treatments.

      In cell cultures and animal models, a potent drug attached to an...

      Read Full Article
      Mentions: Immunotherapy
    9. Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

      Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

      T lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat as the main source of energy. Promoting a switch from glucose to fatty acid to generate energy enhances T cell antitumor activity. These findings from a study conducted at The Wistar Institute were published in the journal Cancer Cell.

      Read Full Article
    10. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      ( Children's Hospital of Philadelphia ) Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy -- harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.

      Read Full Article
    11. RACE for Children Act Becomes Law!

      RACE for Children Act Becomes Law!

      WASHINGTON, Aug. 19, 2017 /PRNewswire/ -- Yesterday, the RACE for Children Act became law, ensuring that novel and exciting new cancer drugs will now be developed not only for adults, but also for children with cancer. Nancy Goodman, CEO of Kids v Cancer stated, "One of the greatest...

      Read Full Article
    12. Research Suggests Turmeric Could Help Fight Cancer in Infants

      Research Suggests Turmeric Could Help Fight Cancer in Infants

      Jessica Miley Turmeric, the spice commonly associated with Indian cooking, has been used by researchers as a treatment for infants with cancer. Neuroblastoma is the most common cancer in infants, affecting 1 in every 7000 children. 90% of the cases of neuroblastoma is found in children under the age of 5, it is a rarely diagnosed in adults.

      Read Full Article
      Mentions: Treatment
    13. CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      Muller Fabbri, MD, PhD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, has been awarded $1.9 million by the National Cancer Institute of the NIH to further his research on neuroblastoma.

      Read Full Article
    14. Neurological Complications of Childhood Cancer.

      Neurological Complications of Childhood Cancer.

      Semin Pediatr Neurol. 2017 Feb;24(1):60-69

      Authors: Weaver L, Samkari A

      Abstract Though the treatment of pediatric cancers has come a long way, acute and chronic effects of cancer are still affecting the life of many children. These effects may be caused not only by the malignancy itself but also by the interventions used for the purpose of treatment.

      Read Full Article
    15. New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      The Treehouse Childhood Cancer Initiative researchers at UC Santa Cruz Genomics Institute and the St. Baldrick's Foundation are making a 11,000+ tumor database available for use by all researchers in the pediatric cancer community and beyond in our continued battle to take childhood back from cancer. The database contains RNA-Seq gene expression data, as well as age, disease, and sex.

      Read Full Article
      Mentions: Genetics
    16. Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

      Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

      After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.

      Read Full Article
    17. New strategy against childhood cancer

      New strategy against childhood cancer

      Neuroblastoma is a cancer in children that originates in the sympathetic nervous system and has a high mortality. Current treatment includes chemotherapy and radiotherapy with their potentially severe side effects; there is therefore an urgent need for a new improved drug. One potential treatment strategy is to use a drug to target deviant molecular signalling caused by changes in genes.

      Read Full Article
    18. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

      Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature.

      Read Full Article
    1-24 of 188 1 2 3 4 5 6 7 8 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) MSKCC
  4. Researches in the News

    1. (3 articles) Antibody
    2. (3 articles) Immunotherapy
    3. (2 articles) Vaccine
  5. General Informations in the News

    1. (1 articles) Treatment
  6. Treatments in the News

    1. (2 articles) Refractory